24 May 2013
Keywords: genzyme, file, bla, fabrazyme, 2q, general, says
Article | 04 May 2000
Genzyme General says it achieved the primary endpoint in a PhaseIII trial of Fabrazyme (afgalsidase beta for injection) for the
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 May 2000
3 May 2000
23 May 2013
© 2013 thepharmaletter.com